Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: Implications for drug safety assessment

Xi Ping Huang, Vincent Setola, Prem N. Yadav, John Allen, Sarah C. Rogan, Bonnie J. Hanson, Chetana Revankar, Matt Robers, Chris Doucette, Bryan L. Roth

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.

Original languageEnglish (US)
Pages (from-to)710-722
Number of pages13
JournalMolecular Pharmacology
Volume76
Issue number4
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Heart Valve Diseases
Safety
Pharmaceutical Preparations
Fenoldopam
Guanfacine
Oxymetazoline
Pergolide
Fenfluramine
Methysergide
Quinidine
Heart Valves
United States Food and Drug Administration
Cluster Analysis
Fibrosis
Pharmacology
Calcium

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists : Implications for drug safety assessment. / Huang, Xi Ping; Setola, Vincent; Yadav, Prem N.; Allen, John; Rogan, Sarah C.; Hanson, Bonnie J.; Revankar, Chetana; Robers, Matt; Doucette, Chris; Roth, Bryan L.

In: Molecular Pharmacology, Vol. 76, No. 4, 10.2009, p. 710-722.

Research output: Contribution to journalArticle

Huang, Xi Ping ; Setola, Vincent ; Yadav, Prem N. ; Allen, John ; Rogan, Sarah C. ; Hanson, Bonnie J. ; Revankar, Chetana ; Robers, Matt ; Doucette, Chris ; Roth, Bryan L. / Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists : Implications for drug safety assessment. In: Molecular Pharmacology. 2009 ; Vol. 76, No. 4. pp. 710-722.
@article{09073e50fd854d9c84fc32b499c822a9,
title = "Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: Implications for drug safety assessment",
abstract = "Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then {"}functionally profiled{"} (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.",
author = "Huang, {Xi Ping} and Vincent Setola and Yadav, {Prem N.} and John Allen and Rogan, {Sarah C.} and Hanson, {Bonnie J.} and Chetana Revankar and Matt Robers and Chris Doucette and Roth, {Bryan L.}",
year = "2009",
month = "10",
doi = "10.1124/mol.109.058057",
language = "English (US)",
volume = "76",
pages = "710--722",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists

T2 - Implications for drug safety assessment

AU - Huang, Xi Ping

AU - Setola, Vincent

AU - Yadav, Prem N.

AU - Allen, John

AU - Rogan, Sarah C.

AU - Hanson, Bonnie J.

AU - Revankar, Chetana

AU - Robers, Matt

AU - Doucette, Chris

AU - Roth, Bryan L.

PY - 2009/10

Y1 - 2009/10

N2 - Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.

AB - Drug-induced valvular heart disease (VHD) is a serious side effect of a few medications, including some that are on the market. Pharmacological studies of VHD-associated medications (e.g., fenfluramine, pergolide, methysergide, and cabergoline) have revealed that they and/or their metabolites are potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We have shown that activation of 5-HT2B receptors on human heart valve interstitial cells in vitro induces a proliferative response reminiscent of the fibrosis that typifies VHD. To identify current or future drugs that might induce VHD, we screened approximately 2200 U.S. Food and Drug Administration (FDA)-approved or investigational medications to identify 5-HT2B receptor agonists, using calcium-based high-throughput screening. Of these 2200 compounds, 27 were 5-HT2B receptor agonists (hits); 14 of these had previously been identified as 5-HT2B receptor agonists, including seven bona fide valvulopathogens. Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fenoldopam, and ropinirole) are approved medications. Twenty-three of the hits were then "functionally profiled" (i.e., assayed in parallel for 5-HT2B receptor agonism using multiple readouts to test for functional selectivity). In these assays, the known valvulopathogens were efficacious at concentrations as low as 30 nM, whereas the other compounds were less so. Hierarchical clustering analysis of the pEC50 data revealed that ropinirole (which is not associated with valvulopathy) was clearly segregated from known valvulopathogens. Taken together, our data demonstrate that patterns of 5-HT2B receptor functional selectivity might be useful for identifying compounds likely to induce valvular heart disease.

UR - http://www.scopus.com/inward/record.url?scp=70349310091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349310091&partnerID=8YFLogxK

U2 - 10.1124/mol.109.058057

DO - 10.1124/mol.109.058057

M3 - Article

C2 - 19570945

AN - SCOPUS:70349310091

VL - 76

SP - 710

EP - 722

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -